摘要
目的观察长春瑞滨(navelbine)+顺铂(cisplatin)NP方案和异环磷酰胺(ifosfamide)+表阿霉素(epirubicin)+顺铂(cisplatin)IAP方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法72例晚期非小细胞肺癌患者随机分为A组(42例)和B组(30例),分别采用NP和IAP方案化疗。结果A组有效率为52．38%(22/42),初治有效率为63．16%(13/20),复治有效率为45．45%(10/22)；B组有效率为46．66%(14/30),初治有效率为62．50%(10/16),复治有效率为35．71%(5/14)。两组间有效率及初治有效率比较差异无统计学意义(P＞0．05),复效有效率A组优于B组(P＜0．05)。两组主要不良反应均为骨髓抑制和恶心呕吐,但差异无统计学意义(P＞0．05)。结论两方案对晚期NSCLC均有较好的疗效,可以耐受,但对于复发病例,选择NP方案似乎更为合适。
Objective To observe the efficacy and side effects of NP and IAP regimens in treatment of advanced non-small cell lung cancer（NSCLC）. Methods 72 patients with advanced NSCLC who were randomly divided in to group A（ n = 42） and group B（ n = 30） were treated individually with NP regimen and IAP regimen. Results In group A, the efficiency rate was 52.38% （22/42）, primary treated efficiency rate was 63.16% （13/20）, retreated efficiency rate was 45.45 % （10/22）. In group B, the efficiency rate was 46.66% （14/30）, primary treated efficiency rate was 62.50 % （ 10/16）, retreated efficiency rate was 35.71% （ 5/14 ）. The retreated efficiency rate in group A was higher than that in group B（P 〈 0.05 ）. There was no significant difference in myelosuppression and in nausea and vomiting between the two groups（P 〉 0.05）. Conclusion Both NP and IAP are effective and tolerable regimens for advanced NSCLC patients, but it seems that NP is better for retreated patients.
出处
《中国基层医药》
CAS
2006年第8期1326-1328,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
癌
非小细胞肺
抗肿瘤联合化疗方案
疗效
Cancer, non-small cell lung
Antineoplastic combined chemotherapy protocols
Curative effect
